Phase 4 N=180 New Stage 1 Formula on Gut Comfort and Gut Health
Health Behavior
Primary: Stool Frequency — 2.2; 2.2; 2.3; 1.6 Times per day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=200 Depression and Anxiety in Rheumatoid Arthritis
Rheumatoid Arthritis · Depression · Anxiety
Primary: Hospital Anxiety and Depression Scale (HADS) — 107; 46; 20; 27 participants
N/A N=53 Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)
Congenital Sucrase-isomaltase Deficiency (CSID)
Primary: Prevalence of CSID Genetic Variants — 27; 0 Participants
N/A N=30 Evaluation of an Absorbable Implant for the Treatment of Nasal Valve Collapse
Nasal Valve Collapse
Primary: Implant-related Adverse Events — 5 participants
N/A N=66 My Mobile Advice Program: A Randomized Pilot Feasibility Study
Smoking Cessation · Medication Adherence
Primary: Point Prevalence Abstinence — 24; 36 Percentage of people not smoking
Phase 2 N=35 Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
Chronic Graft-versus-host Disease
Primary: Change From Baseline (Visit 1) of Total Corneal Fluorescein Staining Score at 12 Weeks. — -4.2; -6.2; -2.1 units on a scale
Phase 2 N=97 E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Stage IV Melanoma
Primary: Dose Limiting Toxicity (DLT) of Lenvatinib Administered in Combination With Dacarbazine (for Phase 1b) — 0; 1; 2; 0 Participants with DLT
N/A N=106 Cocaine Withdrawal and Pharmacotherapy Response
Cocaine Dependence · Opiate Dependence
Primary: Percent Days Abstinent From Cocaine - Self Report — 72.9; 72.9; 59.3 percentage of days — p=.10
Phase 3 N=77 Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Diabetes Mellitus, Type 1
Primary: Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir — 98.7; 100 percentage of participants
Phase 4 N=24 Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir
HIV · Dyslipidemia
Primary: Efficacy of Pitavastatin in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir — 239.9; 257.6; 282; 350 mg/dL — p=<0.05
Phase 3 N=121 Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Primary: Time to Meeting Discharge Criteria (TMDC) — 4.03; 4.00 days — p=0.633
Phase 1 N=15 Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)
Pachyonychia Congenita
Primary: Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels — 15; 15; 15; 14 participants
N/A N=20 Endovascular Repair for the Descending Thoracic Aorta
Aorta Thoracic; Traumatic Rupture
Primary: Number of Participants With Major Adverse Events — 0 number of serious adverse events
N/A N=21 Applying the Use of Motivational Tools to Auditory Rehabilitation
Hearing Loss
Primary: Difference in Hours of Hearing Aid Use Between Pre-intervention and Post-intervention — -2.1; 2.2 hours
Phase 2 N=9 Comparison of Amnion Chorion Membrane vs. Dense Polytetrafluoroethylene Membrane in Ridge Preservation Procedures
Alveolar Bone Loss · Pathological Conditions, Anatomical
Primary: Amount of Preservation of Alveolar Ridge Dimensions i.e..,Clinical Horizontal Ridge Width Change in Millimeter as Result of Ridge Preservation Procedures — 2.54; 2.72…